banner

Cardium to Present at Rodman and Renshaw Conference

Cardium Therapeutics (CXM) Rodman and Renshaw

Cardium to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment Conference

Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J. Reinhard, Chairman & CEO will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Monday, September 10, 2012 at 3:15 p.m. Eastern Time. The conference is being held September 9-11, 2012 at the Waldorf-Astoria Hotel in New York City. An audio webcast of the Company’s presentation will be available live and by replay and can be accessed at http://www.wsw.com/webcast/rrshq22/cxm or at the Investors section of Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar.  An updated investor presentation is now available on Cardium’s website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

About Cardium

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium Health Sciences healthy lifestyle product platform. The Company’s lead commercial product Excellagen® topical gel for wound care management, recently received FDA clearance for marketing and sale in the United States. Cardium’s lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.



Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release or the referenced investor presentation are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®, Excellarate™, Osteorate™, MedPodium®, Appexium®, Linée®, Alena®, Cerex®, D-Sorb™, Neo-Energy®, Neo-Carb Bloc®, Neo-Chill™, and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

Source: Cardium Therapeutics

Cardium Therapeutics, Inc.

Bonnie Ortega

Director, Investor/Public Relations

Tel: (858) 436-1018

Email: [email protected]

Cardium Therapeutics (CXM) Stock Quote and News:







Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated two thousand five hundred dollars by Cardium Therapeutics for its efforts in managing the dissemination of public corporate information on its website and to its database of subscribers and across select financial and social media websites. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

0 comments

Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Tactical Air Defense Services Buying Air 1 Flight Support

Tactical Air Defense Services Buying Air 1 Flight Support(0)

Tactical Air Defense Services, Inc. (Pinksheets: TADF) said Friday morning that it has signed a Letter of Intent to acquire 100 percent of Air 1 Flight Support, Inc. a privately-held provider of aircraft maintenance, refueling and support services headquartered in Denison, Texas, in an all-stock transaction. Tactical Air Defense Services is certified by the U.S.

Electronic Control Security Lands Prime Government Contract

Electronic Control Security Lands Prime Government Contract(0)

Shares of Electronic Control Security, Inc. (OTCBB: EKCS) have soared ahead in Friday morning trading after the company said that it has received a prime contract award from the Department of the Navy, Space and Naval Warfare Systems Center Atlantic (SPAWAR). The Clifton, New Jersey-based provider of integrated entry control and perimeter security systems said

Brightcove Shares Nosedive on Weak 2013 Guidance

Brightcove Shares Nosedive on Weak 2013 Guidance(0)

Coming up on its one-year anniversary of being a public entity, shares of Brightcove, Inc. (NASDAQ: BCOV) printed all-time lows after delivering its fourth-quarter and full 2012 year earnings and a weak outlook for 2013. The provider of cloud-based video streaming services reported total revenue for the fourth quarter of 2012 of $24.3 million, an

Balqon Lithium Battery System Installed in Hybrid Yacht

Balqon Lithium Battery System Installed in Hybrid Yacht(0)

Investors are used to hearing about lithium battery technologies for use in automobiles, but Balqon Corporation (OTCBB: BLQN) is taking them from the street to the water. On Friday, the Harbor City, California-based developer of electric vehicles, drive systems and lithium battery storage systems said that it has delivered and installed its HIQAP high energy

NCAL Bancorp and Grandpoint Capital Terminate Merger Agreement

NCAL Bancorp and Grandpoint Capital Terminate Merger Agreement(0)

NCAL Bancorp (OTCQB: NCAL) and Grandpoint Capital, Inc. said in a joint announcement Tuesday that the two companies have terminated their definitive agreement to merge. Under the agreement, which was entered into in June 2012, Grandpoint was to acquire NCAL Bancorp and its subsidiary National Bank of California. Los Angeles, California-based NCAL and Bank of

read more
banner


Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.